Related Experiment Video
Updated: Jan 19, 2026
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Jose Luis Perez-Gracia1, Miguel F Sanmamed2, Ana Bosch3
1Department of Oncology, University Clinic of Navarra, Pamplona, Spain; Health Research Institute of Navarra (IDISNA), Pamplona, Spain.
Abstract:
The discovery of reliable biomarkers to predict efficacy and toxicity of anticancer drugs remains one of the key challenges in cancer research. Despite its relevance, no efficient study designs to identify promising candidate biomarkers have been established. This has led to the proliferation of a myriad of exploratory studies using dissimilar strategies, most of which fail to identify any promising targets and are seldom validated. The lack of a proper methodology also determines that many anti-cancer drugs are developed below their potential, due to failure to identify predictive biomarkers. While some drugs will be systematically administered to many patients who will not benefit from them, leading to unnecessary toxicities and costs, others will never reach registration due to our inability to identify the specific patient population in which they are active. Despite these drawbacks, a limited number of outstanding predictive biomarkers have been successfully identified and validated, and have changed the standard practice of oncology. In this manuscript, a multidisciplinary panel reviews how those key biomarkers were identified and, based on those experiences, proposes a methodological framework-the DESIGN guidelines-to standardize the clinical design of biomarker identification studies and to develop future research in this pivotal field.
Insights
Identifying reliable biomarkers for anticancer drug efficacy and toxicity is crucial but lacks standardized study designs. This review proposes the DESIGN guidelines to improve biomarker discovery and clinical trial methodology.
Area of Science:
- Oncology
- Biomarker Discovery
- Clinical Trial Design
Background:
- Reliable biomarkers predicting anticancer drug efficacy and toxicity are essential but challenging to discover.
- Current research lacks standardized study designs, leading to numerous failed exploratory studies and underutilized drugs.
- Ineffective biomarker identification results in suboptimal drug development, unnecessary patient toxicity, and increased healthcare costs.
Purpose of the Study:
- To review successful biomarker identification strategies in oncology.
- To propose a standardized methodological framework, the DESIGN guidelines, for biomarker discovery studies.
- To advance future research in identifying predictive biomarkers for anticancer therapies.
Main Methods:
- Multidisciplinary panel review of successful biomarker identification case studies.
- Analysis of existing methodologies and their limitations in biomarker discovery.
- Development of a novel methodological framework (DESIGN guidelines) for clinical study design.
Main Results:
- Identification of key challenges and limitations in current biomarker discovery approaches.
- Proposal of the DESIGN guidelines as a standardized framework for clinical biomarker studies.
- Highlighting the potential of standardized designs to improve drug development and patient outcomes.
Conclusions:
- Standardized clinical study designs are critical for efficient and reliable biomarker identification.
- The proposed DESIGN guidelines offer a roadmap for future research in predictive biomarker development.
- Implementing these guidelines can optimize anticancer drug development and personalize cancer treatment.
Related Concept Videos
01:21Cancer Survival Analysis
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...